The University of Chicago Header Logo

Connection

Ernst Lengyel to Ovarian Neoplasms

Back to Details
This is a "connection" page, showing publications Ernst Lengyel has written about Ovarian Neoplasms.
Ernst Lengyel
Connection Strength
18.988
Ovarian Neoplasms
  1. Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth. Mol Cancer Ther. 2025 Aug 01; 24(8):1252-1264.
    View in: PubMed
    Score: 0.558
  2. NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity. Nature. 2025 09; 645(8082):1051-1059.
    View in: PubMed
    Score: 0.557
  3. Spatial proteo-transcriptomic profiling reveals the molecular landscape of borderline ovarian tumors and their invasive progression. Cancer Cell. 2025 Aug 11; 43(8):1495-1511.e7.
    View in: PubMed
    Score: 0.554
  4. A Proteogenomic View of Synchronous Endometrioid Endometrial and Ovarian Cancer. Clin Cancer Res. 2025 Jun 03; 31(11):2230-2240.
    View in: PubMed
    Score: 0.551
  5. Molecular changes driving low-grade serous ovarian cancer and implications for treatment. Int J Gynecol Cancer. 2024 Oct; 34(10):1630-1638.
    View in: PubMed
    Score: 0.536
  6. Molecular changes driving low-grade serous ovarian cancer and implications for treatment. Int J Gynecol Cancer. 2024 10 07; 34(10):1630-1638.
    View in: PubMed
    Score: 0.527
  7. 5-Hydroxymethylcytosine signals in serum are a predictor of chemoresistance in high-grade serous ovarian cancer. Gynecol Oncol. 2024 03; 182:82-90.
    View in: PubMed
    Score: 0.502
  8. Adipocytes reprogram cancer cell metabolism by diverting glucose towards glycerol-3-phosphate thereby promoting metastasis. Nat Metab. 2023 09; 5(9):1563-1577.
    View in: PubMed
    Score: 0.488
  9. Diagnostic Performance of Ultrasonography-Based Risk Models in Differentiating Between Benign and Malignant Ovarian Tumors in a US Cohort. JAMA Netw Open. 2023 07 03; 6(7):e2323289.
    View in: PubMed
    Score: 0.483
  10. Decoding evolutionary trajectories of ovarian cancer metastasis. Cancer Cell. 2023 06 12; 41(6):1008-1010.
    View in: PubMed
    Score: 0.481
  11. Understanding Long-Term Survival of Patients with Ovarian Cancer-The Tumor Microenvironment Comes to the Forefront. Cancer Res. 2023 05 02; 83(9):1383-1385.
    View in: PubMed
    Score: 0.477
  12. The adipocyte microenvironment and cancer. Cancer Metastasis Rev. 2022 09; 41(3):575-587.
    View in: PubMed
    Score: 0.453
  13. Neoadjuvant Chemotherapy Induces Genomic and Transcriptomic Changes in Ovarian Cancer. Cancer Res. 2022 01 01; 82(1):169-176.
    View in: PubMed
    Score: 0.430
  14. Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment. Obstet Gynecol. 2021 01 01; 137(1):108-121.
    View in: PubMed
    Score: 0.406
  15. Are We Ready for Hyperthermic Intraperitoneal Chemotherapy in the Upfront Treatment of Ovarian Cancer? JAMA Netw Open. 2020 08 03; 3(8):e2014184.
    View in: PubMed
    Score: 0.394
  16. Adipocyte-Induced FABP4 Expression in Ovarian Cancer Cells Promotes Metastasis and Mediates Carboplatin Resistance. Cancer Res. 2020 04 15; 80(8):1748-1761.
    View in: PubMed
    Score: 0.382
  17. Quantitative High-Throughput Screening Using an Organotypic Model Identifies Compounds that Inhibit Ovarian Cancer Metastasis. Mol Cancer Ther. 2020 01; 19(1):52-62.
    View in: PubMed
    Score: 0.372
  18. The road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer. Gynecol Oncol. 2019 02; 152(2):228-234.
    View in: PubMed
    Score: 0.351
  19. The Tumor Microenvironment Takes Center Stage in Ovarian Cancer Metastasis. Trends Cancer. 2018 08; 4(8):517-519.
    View in: PubMed
    Score: 0.341
  20. Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene. 2018 04; 37(17):2285-2301.
    View in: PubMed
    Score: 0.332
  21. Who are the long-term survivors of high grade serous ovarian cancer? Gynecol Oncol. 2018 01; 148(1):204-212.
    View in: PubMed
    Score: 0.326
  22. Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube. Cancer Discov. 2016 12; 6(12):1342-1351.
    View in: PubMed
    Score: 0.303
  23. Microenvironment-induced downregulation of miR-193b drives ovarian cancer metastasis. Oncogene. 2015 Nov 26; 34(48):5923-32.
    View in: PubMed
    Score: 0.272
  24. Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy. Nat Commun. 2015 Feb 05; 6:6220.
    View in: PubMed
    Score: 0.270
  25. Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. Am J Obstet Gynecol. 2015 Apr; 212(4):479.e1-479.e10.
    View in: PubMed
    Score: 0.264
  26. Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. J Clin Invest. 2014 Oct; 124(10):4614-28.
    View in: PubMed
    Score: 0.262
  27. Three-dimensional modeling of ovarian cancer. Adv Drug Deliv Rev. 2014 Dec 15; 79-80:184-92.
    View in: PubMed
    Score: 0.259
  28. Urokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy. Mol Cancer Ther. 2013 Dec; 12(12):2628-39.
    View in: PubMed
    Score: 0.245
  29. Epithelial ovarian cancer experimental models. Oncogene. 2014 Jul 10; 33(28):3619-33.
    View in: PubMed
    Score: 0.243
  30. MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. Cancer Discov. 2012 Dec; 2(12):1100-8.
    View in: PubMed
    Score: 0.231
  31. Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol. 2012 Jan; 119(1):61-7.
    View in: PubMed
    Score: 0.217
  32. The effects of 17ß-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis. Gynecol Oncol. 2012 Jan; 124(1):134-41.
    View in: PubMed
    Score: 0.214
  33. The first line of intra-abdominal metastatic attack: breaching the mesothelial cell layer. Cancer Discov. 2011 Jul; 1(2):100-2.
    View in: PubMed
    Score: 0.210
  34. Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis. Clin Cancer Res. 2011 Jun 15; 17(12):4042-51.
    View in: PubMed
    Score: 0.208
  35. Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis. Clin Cancer Res. 2011 Feb 01; 17(3):459-71.
    View in: PubMed
    Score: 0.202
  36. Ligand-independent activation of c-Met by fibronectin and a(5)ß(1)-integrin regulates ovarian cancer invasion and metastasis. Oncogene. 2011 Mar 31; 30(13):1566-76.
    View in: PubMed
    Score: 0.202
  37. Ovarian cancer development and metastasis. Am J Pathol. 2010 Sep; 177(3):1053-64.
    View in: PubMed
    Score: 0.197
  38. An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis. Neoplasia. 2010 Jan; 12(1):1-10.
    View in: PubMed
    Score: 0.189
  39. {beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. Am J Pathol. 2009 Nov; 175(5):2184-96.
    View in: PubMed
    Score: 0.186
  40. Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice. Cancer Prev Res (Phila). 2009 Sep; 2(9):792-9.
    View in: PubMed
    Score: 0.185
  41. MMP-2 functions as an early response protein in ovarian cancer metastasis. Cell Cycle. 2009 Mar 01; 8(5):683-8.
    View in: PubMed
    Score: 0.179
  42. Organotypic models of metastasis: A three-dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian cancer metastasis. Cancer Treat Res. 2009; 149:335-51.
    View in: PubMed
    Score: 0.177
  43. Does equal treatment yield equal outcomes? The impact of race on survival in epithelial ovarian cancer. Gynecol Oncol. 2008 Nov; 111(2):173-8.
    View in: PubMed
    Score: 0.173
  44. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest. 2008 Apr; 118(4):1367-79.
    View in: PubMed
    Score: 0.168
  45. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res. 2008 Apr 01; 68(7):2329-39.
    View in: PubMed
    Score: 0.168
  46. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res. 2007 Feb 15; 67(4):1670-9.
    View in: PubMed
    Score: 0.155
  47. Rethinking ovarian cancer III: the past decade and future directions. Nat Rev Cancer. 2026 Jun; 26(6):452-471.
    View in: PubMed
    Score: 0.146
  48. Genomic Landscapes of Endometrioid and Mucinous Ovarian Cancers and Morphologically Similar Tumor Types. Cancer Res Commun. 2025 11 01; 5(11):1952-1966.
    View in: PubMed
    Score: 0.142
  49. Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer. Cancer Res. 2025 09 15; 85(18):3471-3489.
    View in: PubMed
    Score: 0.141
  50. Adaptive immune response and PD-1/ PD-L1 status in chemotherapy treated high grade serous carcinoma is dependent on chemotherapy response score. Hum Pathol. 2025 May; 159:105800.
    View in: PubMed
    Score: 0.137
  51. Metformin for patients with advanced stage ovarian cancer: A randomized phase II placebo-controlled trial. Gynecol Oncol. 2025 03; 194:18-24.
    View in: PubMed
    Score: 0.135
  52. Neutrophil extracellular traps promote pre-metastatic niche formation in the omentum by expanding innate-like B cells that express IL-10. Cancer Cell. 2025 Jan 13; 43(1):69-85.e11.
    View in: PubMed
    Score: 0.134
  53. Tumor microenvironment-induced FOXM1 regulates ovarian cancer stemness. Cell Death Dis. 2024 05 28; 15(5):370.
    View in: PubMed
    Score: 0.128
  54. Cancer-associated mesothelial cell-derived ANGPTL4 and STC1 promote the early steps of ovarian cancer metastasis. JCI Insight. 2023 03 22; 8(6).
    View in: PubMed
    Score: 0.118
  55. Ovarian Masses: The Value of Acoustic Shadowing on Ultrasound Examination. J Ultrasound Med. 2023 Apr; 42(4):935-945.
    View in: PubMed
    Score: 0.114
  56. Resilience in the Face of Pandemic: The Impact of COVID-19 on the Psychologic Morbidity and Health-Related Quality of Life Among Women With Ovarian Cancer. JCO Oncol Pract. 2022 06; 18(6):e948-e957.
    View in: PubMed
    Score: 0.110
  57. Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas. Gynecol Oncol. 2021 10; 163(1):130-133.
    View in: PubMed
    Score: 0.106
  58. The Ratio of Toxic-to-Nontoxic miRNAs Predicts Platinum Sensitivity in Ovarian Cancer. Cancer Res. 2021 08 01; 81(15):3985-4000.
    View in: PubMed
    Score: 0.105
  59. Mesothelial Cell HIF1a Expression Is Metabolically Downregulated by Metformin to Prevent Oncogenic Tumor-Stromal Crosstalk. Cell Rep. 2019 12 17; 29(12):4086-4098.e6.
    View in: PubMed
    Score: 0.094
  60. Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer. 2019 06 15; 125(12):1963-1972.
    View in: PubMed
    Score: 0.089
  61. SPHK1 Is a Novel Target of Metformin in Ovarian Cancer. Mol Cancer Res. 2019 04; 17(4):870-881.
    View in: PubMed
    Score: 0.089
  62. Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum. J Exp Med. 2019 01 07; 216(1):176-194.
    View in: PubMed
    Score: 0.088
  63. A 3D tumor microenvironment regulates cell proliferation, peritoneal growth and expression patterns. Biomaterials. 2019 01; 190-191:63-75.
    View in: PubMed
    Score: 0.087
  64. Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis. Cell Metab. 2019 01 08; 29(1):141-155.e9.
    View in: PubMed
    Score: 0.086
  65. Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer. Clin Cancer Res. 2018 11 01; 24(21):5357-5367.
    View in: PubMed
    Score: 0.084
  66. High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer. Gynecol Oncol. 2017 07; 146(1):153-160.
    View in: PubMed
    Score: 0.079
  67. Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention. Cancer Prev Res (Phila). 2017 Apr; 10(4):255-266.
    View in: PubMed
    Score: 0.078
  68. Prolactin Receptor-Mediated Internalization of Imaging Agents Detects Epithelial Ovarian Cancer with Enhanced Sensitivity and Specificity. Cancer Res. 2017 04 01; 77(7):1684-1696.
    View in: PubMed
    Score: 0.078
  69. A High-Throughput Screening Model of the Tumor Microenvironment for Ovarian Cancer Cell Growth. SLAS Discov. 2017 06; 22(5):494-506.
    View in: PubMed
    Score: 0.077
  70. Metformin Targets Central Carbon Metabolism and Reveals Mitochondrial Requirements in Human Cancers. Cell Metab. 2016 11 08; 24(5):728-739.
    View in: PubMed
    Score: 0.076
  71. Exosomes Promote Ovarian Cancer Cell Invasion through Transfer of CD44 to Peritoneal Mesothelial Cells. Mol Cancer Res. 2017 01; 15(1):78-92.
    View in: PubMed
    Score: 0.076
  72. Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status. Nat Commun. 2016 08 26; 7:12645.
    View in: PubMed
    Score: 0.075
  73. Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform. Mol Cancer Ther. 2016 10; 15(10):2282-2293.
    View in: PubMed
    Score: 0.075
  74. Modeling the Early Steps of Ovarian Cancer Dissemination in an Organotypic Culture of the Human Peritoneal Cavity. J Vis Exp. 2015 12 31; (106):e53541.
    View in: PubMed
    Score: 0.072
  75. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015 Nov; 15(11):668-79.
    View in: PubMed
    Score: 0.071
  76. Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer. Oncotarget. 2015 Sep 15; 6(27):23548-60.
    View in: PubMed
    Score: 0.070
  77. Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma. Gynecol Oncol. 2015 Sep; 138(3):656-62.
    View in: PubMed
    Score: 0.069
  78. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015 May 28; 521(7553):489-94.
    View in: PubMed
    Score: 0.069
  79. The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma. Oncotarget. 2015 May 10; 6(13):11342-56.
    View in: PubMed
    Score: 0.069
  80. WNT7A/ß-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer. Oncogene. 2015 Jun; 34(26):3452-62.
    View in: PubMed
    Score: 0.065
  81. Statin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: a retrospective cohort analysis. PLoS One. 2014; 9(8):e104521.
    View in: PubMed
    Score: 0.065
  82. Expression of the homeobox gene HOXA9 in ovarian cancer induces peritoneal macrophages to acquire an M2 tumor-promoting phenotype. Am J Pathol. 2014 Jan; 184(1):271-81.
    View in: PubMed
    Score: 0.062
  83. Summary of the 2013 American Association for Cancer Research (AACR) Annual Meeting. Gynecol Oncol. 2013 Jul; 130(1):6-8.
    View in: PubMed
    Score: 0.060
  84. miR-92a inhibits peritoneal dissemination of ovarian cancer cells by inhibiting integrin a5 expression. Am J Pathol. 2013 May; 182(5):1876-89.
    View in: PubMed
    Score: 0.059
  85. Serial sectioning of the fallopian tube allows for improved identification of primary fallopian tube carcinoma. Gynecol Oncol. 2013 Apr; 129(1):120-3.
    View in: PubMed
    Score: 0.058
  86. HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts. J Clin Invest. 2012 Oct; 122(10):3603-17.
    View in: PubMed
    Score: 0.057
  87. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011 Oct 30; 17(11):1498-503.
    View in: PubMed
    Score: 0.054
  88. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011 Sep 23; 11(10):719-25.
    View in: PubMed
    Score: 0.053
  89. Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. Int J Cancer. 2012 Apr 15; 130(8):1787-97.
    View in: PubMed
    Score: 0.053
  90. The molecular signature of endometriosis-associated endometrioid ovarian cancer differs significantly from endometriosis-independent endometrioid ovarian cancer. Fertil Steril. 2010 Sep; 94(4):1212-1217.
    View in: PubMed
    Score: 0.046
  91. Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. Int J Cancer. 2007 Oct 01; 121(7):1463-72.
    View in: PubMed
    Score: 0.040
  92. Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle. 2007 Nov 01; 6(21):2585-90.
    View in: PubMed
    Score: 0.040
  93. Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci U S A. 2007 Jul 03; 104(27):11400-5.
    View in: PubMed
    Score: 0.040
  94. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res. 2001 Aug; 7(8):2396-404.
    View in: PubMed
    Score: 0.026
  95. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol. 2001 Aug; 82(2):291-8.
    View in: PubMed
    Score: 0.026
  96. Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells. J Biol Chem. 2001 Jul 13; 276(28):26340-8.
    View in: PubMed
    Score: 0.026
  97. Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. Nature. 2019 05; 569(7758):723-728.
    View in: PubMed
    Score: 0.023
  98. Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer. Cell. 2018 09 20; 175(1):159-170.e16.
    View in: PubMed
    Score: 0.022
  99. Involvement of a mitogen-activated protein kinase signaling pathway in the regulation of urokinase promoter activity by c-Ha-ras. J Biol Chem. 1995 Sep 29; 270(39):23007-12.
    View in: PubMed
    Score: 0.018
  100. A phase II, single-arm study of the anti-a5ß1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol. 2011 May 01; 121(2):273-9.
    View in: PubMed
    Score: 0.013
  101. CD95 promotes tumour growth. Nature. 2010 May 27; 465(7297):492-6.
    View in: PubMed
    Score: 0.012
  102. A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings. Appl Immunohistochem Mol Morphol. 2009 Jan; 17(1):57-67.
    View in: PubMed
    Score: 0.011
  103. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008 Apr 01; 22(7):894-907.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.